Ventricular fibrillation
Drug research and approvals for ventricular fibrillation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 55 studies of ventricular fibrillation are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 2 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 55
- Trials authorized in Canada: 0
- FDA orphan approvals: 2
- EU medicines: 0
- Prognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial InfarctionNCT07947498 · Not applicable · Chungnam National University Hospital · starts Aug 2, 2024
- AI-Powered Electrocardiography for Diagnosis and Prognostic Prediction in Cardiovascular Disease (AI-CVD): Multicenter…NCT07856472 · Not reported · Inha University Hospital · starts Mar 1, 2023
- AI-Based Cardiac Analysis Using 12-Lead and 1-Lead ECGNCT07844434 · Not reported · Inha University Hospital · starts Nov 10, 2026
- Analysis of Life-threatening ARrhythMias After Acute Coronary SyndromeNCT07824050 · Not reported · Catharina Ziekenhuis Eindhoven · starts Jul 14, 2026
- Predict Arrhythmia Risk Using Intelligent SoftwareNCT07792694 · Not reported · Catharina Ziekenhuis Eindhoven · starts Jan 1, 2023
- Bundle Branch Pacing to Preserve Ejection Fraction in Atrial Fibrillation TrialNCT07759700 · Not applicable · Poitiers University Hospital · starts Oct 15, 2026
- MAGNEsium With meToprolol for Rate Control In Atrial FibrillationNCT07632157 · Phase 3 · Wake Forest University Health Sciences · starts Nov 10, 2026
- Ventricular Arrhythmias in Acute Myocardial InfarctionNCT07517523 · Not reported · Poitiers University Hospital · starts Jun 20, 2025
- RHYthm and Myocardial Function Relationship Evaluation in Heart DiseasesNCT07491237 · Not reported · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · starts Jun 23, 2026
Approved 2
- AmiodaroneHERG blocker
- BretyliumNorepinephrine transporter substrate
Phase 3 7
- SotalolBeta-1 adrenergic receptor antagonist
- ImipramineSerotonin transporter inhibitor
- MexiletineSodium channel alpha subunit blocker
- ProcainamideSodium channel alpha subunit blocker
- PropranololBeta-1 adrenergic receptor antagonist
- QuinidineSodium channel alpha subunit blocker
- PropafenoneBeta-1 adrenergic receptor antagonist
Phase 2 3
- MetoprololBeta-1 adrenergic receptor antagonist
- EpinephrineAdrenergic receptor agonist
- Celivarone
How its trials ended
147 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 36 whose ending is known, 44% met their primary endpoint, 14% missed it and 42% stopped early.
- Completed, result not reported6645%
- Status unknown2416%
- Ongoing2114%
- Met its primary endpoint1611%
- Missed its primary endpoint53%
- Stopped: other or unclear53%
- Stopped: enrollment or feasibility43%
- Stopped: lack of efficacy21%
- Stopped: sponsor or business decision21%
- Stopped: funding21%
| Jul 2, 2009 | So-AqueousFor use as a substitute for oral sotalol in patients who are unable to take sotalol orally [oral sotalol is indicated for maintenance of… | AltaThera Pharmaceuticals LLC | Approved |
| Aug 3, 1995 | CordaroneFor initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular… | Wyeth-Ayerst Laboratories | Approved |
| Nov 24, 1989 | Bethanidine sulfatePrevention of recurrence of primary ventricular fibrillation. | Medco Research, Inc. | Designated |
| Sep 20, 1988 | Bethanidine sulfateTreatment of primary ventricular fibrillation. | Medco Research, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA